As for the compound’s CNS permeability, while it could be exploited in the context of CNS malignancies like glioblastoma where PKMYT1 is also overexpressed, this property necessitates neurotoxicity evaluation during preclinical development. Here, PKMYT1 is linked to glioblastoma.